Home Stock

Stock Research: Quest Diagnostics

Independent, rules-based stock research to judge this stock's true performance: Cut through market noise and find high-growth or high-value gems from 8,000+ stocks worldwide.

Quest Diagnostics

NYQ:DGX US74834L1008
90
  • Value
    82
  • Growth
    46
  • Safety
    Safety
    89
  • Combined
    83
  • Sentiment
    75
  • 360° View
    360° View
    90
Unlock
What factors are driving this 360° View?
Subscribe to View
Company Description

Quest Diagnostics Incorporated is a provider of diagnostic information services, offering insights from laboratory testing to improve health outcomes. It operates in the diagnostic information services industry, primarily under the Quest Diagnostics brand, and also includes AmeriPath, Dermpath Diagnostics, ExamOne, and Quanum. The company provides broad access to clinical testing through a nationwide network of laboratories and patient service centers, indicating operations primarily in the United States. In the last fiscal year, the company had 45000 employees, a market capitalization of $18578 million, profits of $3273 million, and revenue of $9872 million.

more

ANALYSIS: With an Obermatt 360° View of 90 (better than 90% compared with alternatives) for 2026, overall professional sentiment and financial characteristics for the stock Quest Diagnostics are very positive. The 360° View is based on consolidating four consolidated indicators, with half of the indicators below and half above average for Quest Diagnostics. The consolidated Value Rank has an attractive rank of 82, which means that the share price of Quest Diagnostics is on the lower side compared with typical size in indicators such as revenues, profits, and invested capital. This means the stock price is lower than for 82% of alternative stocks in the same industry. The company is also safely financed with a Safety rank of 89. In addition, professional market sentiment is above average compared with other stock investment alternatives with a Sentiment Rank of 75. But the consolidated Growth Rank has a low rank of 46, which means that the company is below average in terms of growth and momentum when looking at financial metrics such as revenue, profit, and invested capital growth as well as stock returns. 54 of its competitors have better growth. ...read more

more
Strongest Rank Price vs. Earnings (P/E)
Weakest Rank Dividend Yield
Country USA
Industry Health Care Services
Size X-Large
Website questdiagnostics.com
Index
D.J. US Health Care
S&P 500
Quest Diagnostics stock price by TradingView. Not sourced by Obermatt.
Similar Add to Watchlist Similar See Similar Stocks
The higher the 360° View, the better the stock performed against its peers, considering all metrics. The 360° View represents an average of the other 5 ranks and is then scaled to a rank from 1 to 100. The shaded values are illustrative only.
Last update: 13-Mar-2026.

Make Sense of the Ranks

The higher, the better. For every stock, we judge its performance against its peers and rank it on a scale of 1 to 100. These ranks are percentiles: a rank of 75 means the company outperforms 75% of its peers in that specific area. The higher the rank, the better the stock stacks up against its peers.

Value
Identifies how good a value the stock is.
Good Value Expensive
Combined
Consolidated view across Value, Growth, and Safety.
Good Tread Carefully
Growth
Shows a company's growth potential.
High Growth Tough Times
Sentiment
Shows what the market thinks of a stock.
Positive Sentiment Skepticism
Safety
Safety
Assesses how financially secure a company is.
Well-Financed High Leverage
360° View
360° View
Holistic stock analysis: all key non-/financial metrics
Good Watch Out

Detailed and Historical Ranks

Deep dive into 15 detailed ranks and 3 years of history. Unlock the analysis.

Unlock Ranks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2025 2024 2023
Value
82 59 76 83
Growth
46 52 7 37
Safety
Safety
89 11 54 58
Sentiment
75 83 37 89
360° View
360° View
90 45 30 93
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2025 2024 2023
Analyst Opinions
9 52 28 40
Opinions Change
50 43 25 55
Pro Holdings
n/a 100 55 95
Market Pulse
94 94 71 78
Sentiment
75 83 37 89
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2025 2024 2023
Value
82 59 76 83
Growth
46 52 7 37
Safety Safety
89 11 54 58
Combined
83 18 35 78
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2025 2024 2023
Price vs. Sales (P/S)
84 16 20 34
Price vs. Earnings (P/E)
7 44 61 54
Price vs. Book (P/B)
45 38 50 71
Dividend Yield
100 93 94 92
Value
82 59 76 83
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2025 2024 2023
Revenue Growth
57 29 12 5
Profit Growth
98 54 27 66
Capital Growth
19 42 28 33
Stock Returns
38 75 23 71
Growth
46 52 7 37
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2025 2024 2023
Leverage
19 36 46 52
Refinancing
95 19 27 37
Liquidity
89 26 71 71
Safety Safety
89 11 54 58

Similar Stocks

Discover high‑ranked alternatives to Quest Diagnostics and broaden your portfolio horizons.

Micron

NSQ:MU
Country: USA
Industry: Semiconductors
Size: XX-Large
Full Stock Analysis

ResMed

NYQ:RMD
Country: USA
Industry: Health Care Equipment
Size: X-Large
Full Stock Analysis

Zimmer

NYQ:ZBH
Country: USA
Industry: Health Care Equipment
Size: X-Large
Full Stock Analysis

Resideo Technologies

NYQ:REZI
Country: USA
Industry: Building Products
Size: Large
Full Stock Analysis

Frequently Asked
Questions

The stock offers good value, safe financing, and positive sentiment. However, it has below-average growth expectations. It is well-suited for conservative buy-and-hold investors who prioritize stability and low valuation over growth.

Obermatt provides unbiased stock analysis as a completely independent third party. We have no conflicts of interest with individual stock titles. Our data-driven analysis is based on algorithms honed over twelve years, giving you analysis that is free from personal bias and conflicts of interest.

The 360° View Rank indicates a company's overall performance across all major financial and non-financial metrics tracked by Obermatt. A 360° View Rank of 75 means the company is more well-rounded than 75% of similar companies. A high score indicates that the company is strong across the board; it is attractively priced, growing sustainably, financially stable, and well-regarded by the market. Learn more.

Become an Obermatt subscriber and see all of the similar stocks here.

OTHER FEATURES

Use the Platform to its Fullest

The Obermatt Advantage

Ready to Elevate Your Investing?
Get Started Today

Choose the Obermatt subscription that best fits your needs.


30-day money back guarantee. Your subscription will renew until you cancel it, which you can do at any time.

What Our Customers Say

See how Obermatt improved their investing:

Review us See More Google Reviews